Vulvo-vaginal restoration
In women, aging is accompanied by the menopause (loss of reproductive capacity and estrogen deficiency). The age of menopause is around 50, and a woman's life expectancy at birth in France and Europe is around 87, which means she should live more than 30 years post-menopause. This estrogen deficiency is responsible for changes in the vulvovaginal region with loss of vaginal homeostasis (loss of trophicity, hydration, elasticity, changes in vaginal and bladder microbiota), leading to vaginal dryness, discomfort, pain during intercourse and urinary disorders. These changes are part of the genitourinary syndrome of the menopause.
Other factors can influence disorders of the vulvovaginal region throughout a woman's life. Close pregnancies, late pregnancy, instrumental delivery, macrosomia, weight variation
Treatments such as radiotherapy, chemotherapy and surgery.
Treating disorders of the vulvo-vaginal region is one of the essential levers for improving the quality of life of post-menopausal women and contributing to healthy life expectancy.
In recent years, the arrival of minimally invasive therapies has added to the therapeutic arsenal of existing local treatments (hormonal therapies, moisturizing lubricants).
These minimally invasive therapies have demonstrated their efficacy and safety in the treatment of vulvovaginal atrophy, and are currently being evaluated for the treatment of urinary incontinence.
Various modalities are currently available, requiring training for the operator. These include lasers (CO2 or Erbium), radiofrequency, photo biomodulation and hyaluronic acid injections.)
More invasive techniques such as PRP (platelet-rich plasma) and nanoFat (stem cells) are also used.
This entire therapeutic arsenal enables personalized, preventive and progressive management of changes in the vulvo-vaginal region.
Personally, my experience in oncology has aroused my interest in these new therapies. I've been using CO2 laser and hyaluronic acid injections for over 5 years.
